which already has an FDA green light for its Igalmi (dexmedetomidine) drug in agitation associated with schizophrenia and bipolar disorder, and has a phase 3 programme running in Alzheimer’s ...

which is currently under FDA review. Approval for a monthly IV dose of Leqembi is also being sought. The Alzheimer’s Drug Discovery Foundation (ADDF) also welcomed the approval, saying it would ...

A chemist a UAlbany and his son are looking to make a major breakthrough in the world of Alzheimer's prevention. They believe ...

According to the FDA, the drug is approved for people with early symptomatic Alzheimer’s disease, which includes mild cognitive impairment and those with the mild dementia stage of Alzheimer’s ...

THURSDAY, Sept. 11, 2024 (HealthDay News) -- Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab ...

The new Alzheimer’s drug Kinsula is offering hope for patients by slowing down the progression of the disease. Neurologist Dr. Mauricio Concha administered the drug ...

If the European Medicines Agency takes an overly cautious approach to selecting specialists to advise on new medicines, ...

Researchers have found that an Alzheimer's drug ... like torpor state using donepezil (DNP), a drug approved by the FDA to treat Alzheimer's. The team had previously used another drug, SNC80 ...

Researchers have discovered that Alzheimer's drugs Leqembi and Kisunla boost levels of a healthy form of protein in the brain, even as they reduce its more toxic form.

The first drug found to slow down Alzheimer’s is to be given the green light for use in Britain. Lecanemab, hailed by experts as “the beginning of the end” for the disease, has been found to ...

This is what the drug is designed to do, prohibit these amyloid plaque deposits from forming. Experts say that it is still an open question how Alzheimer’s manifests in people with Down ...